8-K: Titan Pharmaceuticals Secures $1 Million Investment via Convertible Preferred Stock Offering

Titan Pharmaceuticals enters into a securities purchase agreement with Blue Harbour Asset Management, issuing Series B Convertible Preferred Stock for $1 million to bolster its financial position.

Summary

• Titan Pharmaceuticals has entered into a Securities Purchase Agreement with Blue Harbour Asset Management L.L.C-FZ, issuing 100,000 shares of Series B Convertible Preferred Stock at $10.00 per share, totaling $1,000,000.
• The Series B Preferred Stock is convertible into common stock at a conversion price of $3.00, subject to adjustments.
• Based on the initial conversion rate, approximately 333,333 shares of common stock would be issuable upon conversion of all Series B Preferred Stock.
• The investor is restricted from acquiring more than 19.99% of the company's outstanding common stock without shareholder approval.
• Holders of the Series B Preferred Stock are entitled to dividends equivalent to those paid on common stock on an as-if-converted basis.
• The company cannot alter the rights of the Series B Preferred Stock, amend its charter documents adversely, increase the number of authorized shares of Series B Preferred Stock, or enter into a Fundamental Transaction without the approval of a majority of the Series B Preferred Stock holders.
• In a liquidation event, Series B Preferred Stock holders will receive the same amount as common stock holders on an as-if-converted basis.
• The company received a notice from Nasdaq stating that it does not meet the continued listing requirement due to stockholders' equity being below $2,500,000, reporting $2,440,000.
• The company intends to submit a compliance plan within 45 days to regain compliance and may be granted up to 180 days to evidence compliance.
• Gabriel Loh has been appointed as an independent director and a member of the Audit Committee.

Sentiment

Score: 4

Explanation: The announcement is mixed. While the capital injection is positive, the Nasdaq listing deficiency and potential dilution raise concerns. The sentiment is cautiously optimistic.

Positives

• The $1 million investment provides Titan Pharmaceuticals with additional capital.
• The appointment of an independent director may improve corporate governance.
• The company is taking steps to address the Nasdaq listing deficiency.

Negatives

• The company is not in compliance with Nasdaq's continued listing requirements.
• The issuance of convertible preferred stock will dilute existing shareholders upon conversion.
• The company's stockholders' equity is below the required minimum.

Risks

• Failure to regain compliance with Nasdaq listing rules could result in delisting.
• Dilution from the conversion of preferred stock could negatively impact the value of existing shares.
• The company's financial condition may be precarious, as evidenced by the need for additional funding and the Nasdaq listing deficiency.

Future Outlook

The company expects the closing of the Private Placement to occur the week of April 7, 2025, and intends to submit a compliance plan to Nasdaq within 45 days to regain compliance with listing rules.

Industry Context

Small cap pharmaceutical companies often rely on private placements to fund operations and development. The use of convertible preferred stock is a common mechanism, allowing investors potential upside while providing downside protection. The Nasdaq listing deficiency highlights the financial challenges faced by many companies in this sector.

Comparison to Industry Standards

• Comparable companies in the small-cap pharmaceutical space, such as Aeterna Zentaris and Biofrontera, have also utilized convertible securities to raise capital.
• The conversion price of $3.00 is within the typical range observed in similar financings, but the specific terms depend heavily on the company's valuation and perceived risk.
• The 19.99% ownership limitation is a standard provision to avoid triggering shareholder approval requirements under Nasdaq rules, similar to what is seen in offerings by companies like Diffusion Pharmaceuticals.
• The timeline for submitting a compliance plan to Nasdaq (45 days) and the potential extension (up to 180 days) are standard procedures for companies facing listing deficiencies, as seen with companies like Evofem Biosciences.

Management Changes

Stakeholder Impact

• Shareholders will experience dilution upon conversion of the preferred stock.
• The company's employees and customers may be affected by the company's financial stability.
• The company's creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• The company will close the private placement the week of April 7, 2025.
• The company will submit a compliance plan to Nasdaq within 45 days.
• The company will evaluate available options to resolve the deficiency and regain compliance.

Key Dates

Keywords

Convertible Preferred Stock, Private Placement, Nasdaq Listing, Stockholders Equity, Titan Pharmaceuticals, Blue Harbour Asset Management, Compliance Plan, Independent Director, Capital Raise